Historical Valuation
Beta Bionics Inc (BBNX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 10.50 is considered Overvalued compared with the five-year average of -10.38. The fair price of Beta Bionics Inc (BBNX) is between 12.19 to 19.35 according to relative valuation methord. Compared to the current price of 20.14 USD , Beta Bionics Inc is Overvalued By 4.08%.
Relative Value
Fair Zone
12.19-19.35
Current Price：20.14
4.08%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Beta Bionics Inc (BBNX) has a current Price-to-Book (P/B) ratio of 4.37. Compared to its 3-year average P/B ratio of 2.08 , the current P/B ratio is approximately 110.04% higher. Relative to its 5-year average P/B ratio of 2.08, the current P/B ratio is about 110.04% higher. Beta Bionics Inc (BBNX) has a Forward Free Cash Flow (FCF) yield of approximately -4.70%. Compared to its 3-year average FCF yield of -7.39%, the current FCF yield is approximately -36.43% lower. Relative to its 5-year average FCF yield of -7.39% , the current FCF yield is about -36.43% lower.
P/B
Median3y
2.08
Median5y
2.08
FCF Yield
Median3y
-7.39
Median5y
-7.39
Competitors Valuation Multiple
AI Analysis for BBNX
The average P/S ratio for BBNX competitors is 8.04, providing a benchmark for relative valuation. Beta Bionics Inc Corp (BBNX.O) exhibits a P/S ratio of 10.50, which is 30.5% above the industry average. Given its robust revenue growth of 63.14%, this premium appears sustainable.
Performance Decomposition
AI Analysis for BBNX
1Y
3Y
5Y
Market capitalization of BBNX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BBNX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BBNX currently overvalued or undervalued?
Beta Bionics Inc (BBNX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 10.50 is considered Overvalued compared with the five-year average of -10.38. The fair price of Beta Bionics Inc (BBNX) is between 12.19 to 19.35 according to relative valuation methord. Compared to the current price of 20.14 USD , Beta Bionics Inc is Overvalued By 4.08% .
What is Beta Bionics Inc (BBNX) fair value?
BBNX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Beta Bionics Inc (BBNX) is between 12.19 to 19.35 according to relative valuation methord.
How does BBNX's valuation metrics compare to the industry average?
The average P/S ratio for BBNX's competitors is 8.04, providing a benchmark for relative valuation. Beta Bionics Inc Corp (BBNX) exhibits a P/S ratio of 10.50, which is 30.50% above the industry average. Given its robust revenue growth of 63.14%, this premium appears sustainable.
What is the current P/B ratio for Beta Bionics Inc (BBNX) as of Jan 11 2026?
As of Jan 11 2026, Beta Bionics Inc (BBNX) has a P/B ratio of 4.37. This indicates that the market values BBNX at 4.37 times its book value.
What is the current FCF Yield for Beta Bionics Inc (BBNX) as of Jan 11 2026?
As of Jan 11 2026, Beta Bionics Inc (BBNX) has a FCF Yield of -4.70%. This means that for every dollar of Beta Bionics Inc’s market capitalization, the company generates -4.70 cents in free cash flow.
What is the current Forward P/E ratio for Beta Bionics Inc (BBNX) as of Jan 11 2026?
As of Jan 11 2026, Beta Bionics Inc (BBNX) has a Forward P/E ratio of -18.11. This means the market is willing to pay $-18.11 for every dollar of Beta Bionics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Beta Bionics Inc (BBNX) as of Jan 11 2026?
As of Jan 11 2026, Beta Bionics Inc (BBNX) has a Forward P/S ratio of 10.50. This means the market is valuing BBNX at $10.50 for every dollar of expected revenue over the next 12 months.